Articles

As a nine-year project to build vaccine development capacity worldwide comes to an end, PATH and partners reflect on how far we’ve come.

Improving vaccine coverage rates and vaccine acceptability in Serbia are critical issues. Locally made vaccines might be a part of the solution.

Serbia’s Institute of Virology, Vaccines, and Sera “Torlak” is a trusted, recognized vaccine producer in Serbia. As part of the influenza vaccine development project, it conducted its first complex vaccine clinical trial in humans, which helps position Torlak as an essential vaccine producer for the Balkan region.

An incurable disease sometimes referred to as “brain fever” once ravaged communities across Asia. But thanks to PATH and our partners, Japanese encephalitis is no longer the threat it once was. A 20-year effort turned a little-known vaccine from China into an internationally approved immunization tool. The vaccine has now reached more than 300 million children—a turning point in the battle to protect people from this dreaded disease.